Trial Profile
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ZUMA-4
- Sponsors Kite Pharma
- 23 Jun 2023 Planned End Date changed from 1 Aug 2038 to 1 Aug 2027.
- 23 Jun 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2025.
- 23 Jun 2023 Status changed from active, no longer recruiting to recruiting.